Plus   Neg

Citigroup, ValueAct Capital Reach Information Sharing And Engagement Deal

Citigroup Inc. (C) and ValueAct Capital said that they reached an Information Sharing and Engagement Agreement which will formalize and expand on the constructive dialogue between Citi and ValueAct that began in early 2018.

Citigroup noted that the Agreement enables ValueAct to have access to confidential information about the company and engage with members of Citi's management team and Board of Directors on areas such as strategy, governance and operational planning matters.

The Agreement also provides for ValueAct's support for management and the Board through the term of the Agreement, which lasts through December of 2019.
A representative of ValueAct currently sits on the board of Alliance Data Systems, a competitor of Citi's in certain business lines.

Due to issues around board interlocks of competitors, ValueAct is not pursuing a board seat at Citi at this time. Citi and ValueAct have discussed that when this situation changes, it is likely that ValueAct will propose a candidate for a board seat and Citi would consider the request, following its usual process for director candidates, Citigroup said.

Citi CEO Michael Corbat said, "We have had a very constructive dialogue with ValueAct over the past year. This Agreement will enable Citi to work closely with one of its largest shareholders and one with unique insights and a strong track record of adding value to global organizations..."

ValueAct currently owns approximately 32 million of the issued and outstanding shares of Citigroup common stock and is one of its largest shareholders.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT